Nasdaq

Summit Therapeutics plc : Holding(s) in Company

21-09-2017

TR-1: S
tandard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS
 
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached
ii
:
SUMMIT THERAPEUTICS PLC
1b. Please indicate if the issuer is a non-UK issuer  
(please mark with an "X" if appropriate)
Non-UK issuer  
2. Reason for the notification
(please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments  
An event changing the breakdown of voting rights  
Other (please specify)
iii
:
 
3. Details of person subject to the notification obligation
iv
Name CANACCORD GENUITY GROUP INC
City and country of registered office (if applicable) VANCOUVER, CANADA
4. Full name of shareholder(s)
(if different from 3.)
v
Name DISCRETIONARY CLIENTS




 
City and country of registered office (if applicable)  
5. Date on which the threshold was crossed or reached
vi
:
18 SEPTEMBER 2017
6. Date on which issuer notified (DD/MM/YYYY): 21 SEPTEMBER 2017
7. Total positions of person(s) subject to the notification obligation
  % of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments


(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B) Total number of voting rights of issuer
vii
Resulting situation on the date on which threshold was crossed or reached 4.1548% N/A 4.1548% 70,316,908
Position of previous notification (if


applicable)
N/A N/A N/A  




8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
viii
A: Voting rights attached to shares

Class/type of


shares



ISIN code (if possible)
Number of voting rights
ix
% of voting rights
Direct


(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect


(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct


(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect


(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BN40HZ01   2,921,500   4.1548%
         
         
SUBTOTAL 8. A 2,921,500 4.1548%
 




 
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument
Expiration


date

x

Exercise/


Conversion Period

xi
Number of voting rights that may be acquired if the instrument is


exercised/converted.
% of voting rights
         
         
         
    SUBTOTAL 8. B 1    
 




 
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument
Expiration


date

x

Exercise/


Conversion Period

xi
Physical or cash


settlement
xii
Number of voting rights % of voting rights
           
           
           
      SUBTOTAL 8.B.2    
 




 




 


9. Information in relation to the person subject to the notification obligation
(please mark the


applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer
xiii
 
Full
chain of controlled undertakings through which the voting rights and/or the


financial instruments are effectively held starting with the ultimate controlling natural person or legal entity
xiv
(please add additional rows as necessary)
X
Name
xv
% of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Canaccord Genuity Group Inc.

[1]
4.1548%   4.1548%
       
Canaccord Genuity Wealth Group Holdings Limited 4.1548%   4.1548%
Canaccord Genuity Wealth Group Holdings (Jersey) Limited 4.1548%   4.1548%
Hargreave Hale Limited 4.1548%   4.1548%
[1] Each company set out in this table is ultimately owned by Canaccord Genuity Group Inc.




 
10.
In case of proxy voting, please identify:
Name of the proxy holder  
The number and % of voting rights held  
The date until which the voting rights will be held  
 
11. Additional information
xvi
This disclosable event is as a result of the acquisition of Hargreave Hale Limited by Canaccord Genuity Group Inc., through its wholly-owned subsidiary Canaccord Genuity Wealth Group Holdings (Jersey) Limited.




 




 


Place of completion London
Date of completion 21 September 2017

           





This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Summit Therapeutics plc via GlobeNewswire

HUG#2136033